Sulfated C19 steroid hormones to treat and/or prevent proteotoxicity in protein-aggregation diseases

1 . A method for the treatment of proteotoxicity in a protein-aggregation disease in a subject, wherein the protein-aggregation disease is Alzheimer's disease or Parkinson's disease, comprising administering a composition comprising sulfated C19 androgens selected from the group consisting of testosterone sulfate (TS), or any salts or esters thereof, and epitestosterone sulfate (ES), or any salts or esters thereof, to the subject.

2 . A method for slowing down the progression of a protein-aggregation disease by inhibiting the formation of protein aggregates and/or delaying the onset of the protein-aggregation disease by inhibiting the formation of protein aggregates, wherein the protein-aggregation disease is Alzheimer's disease, or Parkinson's disease, comprising administering a composition comprising sulfated C19 androgens selected from the group consisting of testosterone sulfate (TS), or any salts or esters thereof, and epitestosterone sulfate (ES), or any salts or esters thereof, to the subject.

3 . The method according to claim 1 , wherein the composition is simultaneously or subsequently administered with a sulfatase inhibitor selected from the group consisting of 2-(hydroxyphenyl) indol sulfate, 5-androstene-3β, DU-14 (CAS NO: 186303-55-9), COUMATE (4-methylcoumarin-7-O-sulphamate), EMATE (CAS Number: 148672-09-7), and the sulfatase inhibitor of Formula (I):

wherein:

R1-R6 are independently selected from hydrogen, halogen, hydroxyl, sulfamate, alkyl and salts thereof;

at least one of R1-R6 is a sulfamate group; and

two or more of R1-R6 are linked together to form an additional cyclic structure.

4 . The method according to claim 3 , wherein the sulfatase inhibitor is compound STX64 of Formula (II):

or any salts thereof.

5 . The method according to claim 1 , wherein the composition is a pharmaceutical composition comprising the C19 androgens and optionally a pharmaceutically acceptable carrier and/or diluent.

6 . The method according to claim 1 , wherein the composition is a nutraceutical composition.

7 . The method according to claim 1 , wherein the composition is a dietary supplement.

8 . The method according to claim 1 , wherein the composition is administered orally.

9 . The method according to claim 2 , wherein the composition is simultaneously or subsequently administered with a sulfatase inhibitor selected from the group consisting of 2-(hydroxyphenyl) indol sulfate, 5-androstene-3β, DU-14 (CAS NO: 186303-55-9), COUMATE (4-methylcoumarin-7-O-sulphamate), EMATE (CAS Number: 148672-09-7), and the sulfatase inhibitor of Formula (I):

wherein:

R1-R6 are independently selected from hydrogen, halogen, hydroxyl, sulfamate, alkyl and salts thereof;

at least one of R1-R6 is a sulfamate group; and

two or more of R1-R6 are linked together to form an additional cyclic structure.

10 . The method according to claim 9 , wherein the sulfatase inhibitor is compound STX64 of Formula (II):

or any salts thereof.

11 . The method according to claim 2 , wherein the composition is a pharmaceutical composition comprising the C19 androgens and optionally a pharmaceutically acceptable carrier and/or diluent.

12 . The method according to claim 2 , wherein the composition is a nutraceutical composition.

13 . The method according to claim 2 , wherein the composition is a dietary supplement.

14 . The method according to claim 2 , wherein the composition is administered orally.